CVE:HEM Hemostemix (HEM) Stock Price, News & Analysis C$0.07 0.00 (0.00%) As of 09/11/2026 12:11 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartInsider TradesNews and Trends About Hemostemix Stock (CVE:HEM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Hemostemix alerts:Sign Up Key Stats Today's RangeC$0.07▼C$0.0750-Day RangeC$0.05▼C$0.0852-Week RangeC$0.04▼C$0.13Volume37,900 shsAverage Volume44,192 shsMarket CapitalizationC$14.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada. Read More Receive HEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hemostemix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HEM Stock News HeadlinesHemostemix (CVE:HEM) Stock Price Passes Above 50-Day Moving Average - Here's What HappenedSeptember 12 at 3:53 AM | americanbankingnews.comHemostemix (CVE:HEM) Stock Price Crosses Above Fifty Day Moving Average - What's Next?September 3, 2026 | americanbankingnews.comBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 million shares worth about 716 million dollars, while Vanguard owns 48 million shares worth nearly 1.1 billion dollars. The company generates approximately 3.2 billion dollars in operating income against a market value of only about 8 billion dollars, and it has signed a multi-year AI agreement with Palantir to improve equipment reliability and well performance.September 14 at 1:00 AM | Monument Traders Alliance (Ad)Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTAAugust 20, 2026 | finance.yahoo.comDr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical TrialAugust 13, 2026 | finance.yahoo.comHemostemix Raises CDN$322,250 in Second Tranche of Private PlacementAugust 6, 2026 | tipranks.comHemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026July 30, 2026 | theglobeandmail.comHemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent ResultsJuly 28, 2026 | finance.yahoo.comSee More Headlines HEM Stock Analysis - Frequently Asked Questions How have HEM shares performed this year? Hemostemix's stock was trading at C$0.09 at the beginning of 2026. Since then, HEM stock has decreased by 22.2% and is now trading at C$0.07. How do I buy shares of Hemostemix? Shares of HEM stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Hemostemix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hemostemix investors own include Iplayco (IPC), Capricor Therapeutics (CAPR), Golden Share Resources (GSH), Nuvilex (PMCB), Algernon Pharmaceuticals (AGNPF), Defense Metals (DFMTF) and NIO (NIO). Industry, Sector and Symbol Stock ExchangeCVE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolCVE:HEM CIKN/A Webwww.hemostemix.com Phone+1-403-3409207FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$5.00 million Net MarginsN/A Pretax MarginN/A Return on Equity92.37% Return on Assets-349.24% Debt Debt-to-Equity Ratio-61.85 Current Ratio0.13 Quick Ratio0.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.01 per share Price / Cash Flow10.77 Book ValueC($0.03) per share Price / Book-2.49Miscellaneous Outstanding Shares204,996,000Free FloatN/AMarket CapC$14.35 million OptionableNot Optionable Beta0.31 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (CVE:HEM) was last updated on 9/14/2026 by MarketBeat.com Staff. From Our PartnersThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredPrint this before your next tradeBill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It'...Profits Run | SponsoredWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...Stansberry Research | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredThis little-known gold fund distributes cash every FridayGold pays no dividends, no interest, no yield - it just sits there. Yet investors are reportedly collecting up...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemostemix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemostemix With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HEM Stock Alerts